AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|
14.1 C
New York
Friday, October 30, 2026

Tag: function

newsFORsourcecompanycontentinformationreleases1market

OMS Energy Technologies Inc. Issues Post-IPO Operational Update Featuring Customer Growth, Expansion Initiatives and R&D and Safety Achievements

SINGAPORE, June 16, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate...

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Powerful, Compact, Smart: Jackery Launches the Lightest 3kWh Explorer 3000 v2

LONDON, June 16, 2025 /PRNewswire/ -- Jackery, a leading provider of portable power solutions, unveils its latest flagship model: the Explorer 3000 v2 — the brand's...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Aslan Energy Capital and JIEP Sign Heads of Agreement to Develop East Jakarta’s Renewable-Powered Hyperscale Data Center

JAKARTA, Indonesia, June 14, 2025 /PRNewswire/ -- Aslan Energy Capital (AEC), a Singapore-based developer of clean energy infrastructure, has signed a binding Heads of...

IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1

Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to the latest IDC Worldwide Quarterly Wearable Device Tracker data, Huawei...

UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research

VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support...

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

Weekly Recap: 11 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea treatments, fall detection for seniors...

Airis NEO P40000: Redefining Disposable Vapes, Delivering a Premium Experience of Pure and Smooth Vaping

SHENZHEN, China, June 13, 2025 (GLOBE NEWSWIRE) -- As a leading brand in the global vaping industry, Airis once again redefines industry expectations with the launch of its latest flagship product, the NEO P40000. This revolutionary product integrates an intelligent monitoring system, triple-core ultra-fast vaporization, five-level nicotine adjustment, and 15 authentic flavors, it not only redefines the user experience of disposable e-cigarettes but also leads global users into a new era of “smart, premium, and long-lasting” vaping.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFunction

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers